跳至主要内容
临床试验/NCT03504202
NCT03504202Unknown不适用

Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)

Shanghai 10th People's Hospital0 个研究点目标入组 10 人开始时间: 2019年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
10
主要终点
Coronary flow reserve (CFR) improves

研究概览

简要总结

This is a prospective study which aims to explore the effect of Trimetazidine on the improvement of coronary microvascular dysfunction in patients with INOCA (ischemia and no obstructive coronary artery disease). Enrolled patients will be assessed SAQ(Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR(coronary flow reserve) .CFR inspection with D-SPECT and pressure guide wire.Patients will receive six months Trimetazidine(35mg tid) after enrollment. And their SAQ (Seattle Angina Score), Canadian Angina Grade(Canadian Cardiovascular Society, CCS), Six-Minute Walk Test, CFR will be followed up.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age≥18 years
  • Typical angina symptoms
  • Coronary angiography or coronary computed tomography examination showed no significant epicardial coronary artery stenosis (<20%)
  • Never used trimetazidine
  • The CFR measured by the pressure guide wire is less than 2.0
  • agree to participant the study and sign informed written consent
  • available for six months follow up

排除标准

  • Severe liver and kidney disease
  • Contraindications of Trimetazidine
  • Use of CYP3A inhibitors, such as diltiazem, verapamil, and other drugs that may affect CFR measurements
  • QT interval extension
  • Atrial fibrillation or left bundle branch block
  • Left ventricular systolic dysfunction (EF <55%)
  • Coronary artery fistula
  • Myocardial bridge
  • Non-cardiogenic chest pain and other heart diseases
  • Severe heart valve disease
  • Recent ACS( Acute coronary syndrome)
  • Pregnancy
  • Failed to complete inspection

研究组 & 干预措施

Trimetazidine

Experimental

干预措施: Trimetazidine (Drug)

结局指标

主要结局

Coronary flow reserve (CFR) improves

时间窗: six months

次要结局

  • Seattle angina score or Canadian angina grade drops(six months)
  • Six-minute walking experiment improves(six months)

研究者

发起方
Shanghai 10th People's Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ya-Wei Xu

The chief director of department of cardiology

Shanghai 10th People's Hospital

相似试验